Table 1 Demographic and clinical characteristics of patients with SSc and control subjects
From: Inhibition of angiogenesis by platelets in systemic sclerosis patients
Characteristic | Patients (n = 30) | Control subjects (n = 12) |
|---|---|---|
Female sex, % | 96.6 | 91.6 |
Age, yr, mean (SD) | 51.3 (16.8) | 41.9 (14.7) |
Disease duration, mo, mean (SD) | 128.5 (18.4) | |
Disease subset | ||
Diffuse systemic sclerosis, % | 17.2 | |
Limited systemic sclerosis, % | 82.8 | |
ANA positivity (>1:80), % | 100 | 0 |
Centromere, % | 71.4 | |
Nucleolar, % | 3.7 | |
Other, % | 25 | |
Anti-Scl-70 | 16.1 | |
Anti-RNA polymerase III | 6.7 | |
ESR, mm/h, mean (SD) | 32.7 (33.6) | |
Hemoglobin, g/dl, mean (SD) | 12.5 (1.2) | |
WBC, n/μl, mean (SD) | 7288.21 (2836.6) | |
Platelets, 109/L, mean (SD) | 245 (65) | |
CRP, mg/L, mean (SD) | 0.47 (0.5) | |
Ultrasensitive CRP μg/ml, mean (SD) | 12.24 (28.2) | 5.08 (1.0) |
Complement component C3, mg/dl, mean (SD) | 104.42 (20.2) | |
Complement component C4, mg/dl, mean (SD) | 17.42 (5.79) | |
Raynaud’s phenomenon, % | 89.66 | |
Gastrointestinal symptoms, % | 75.0 | |
Digital ulcers, % | 31.3 | |
Calcinosis, % | 17.2 | |
Lung fibrosis, % | 23.3 | |
Pulmonary arterial hypertension, % | 13.3 | |
Current therapies, % | ||
Mycophenolate mofetil | 16.7 | |
Methotrexate | 26.7 | |
Cyclophosphamide | 6.7 | |
Prednisone | 18.7 |